Subsequent assays implied that the nanomedicine could significantly inhibit the expression of Ang II-induced angiogenesis related gene VEGF, which the inhibition rate achieved 83%; moreover, anticancer efficacy in vivo displayed an important tumor growth inhibition efficacy and the final tumor volume was below 500 mm3, far less than that in other groups. This evidence concerns the gene VEGFA and neoplasm.